#breastcancer #NICE #NHS #HEOR #Enhertu #AstraZeneca #DaiichiSankyo #Oncology #HER2lowbreastcancer #incurablebreastcancer #NICEFinaldraftguidance #reimbursement #metastaticbreastcancer #NICEcosteffectivenessthreshold #NICErecommendation #CancerDrugsFund #NHScommissioning
zurl.co/eYPtT